(Q51170709)

31 March 2018

title

Cost of multiple sclerosis in the Czech Republic: the COMS study. (English)

1 reference

31 March 2018

0 references

1 reference

2

1 reference

31 March 2018

author name string

J Blahova Dusankova

1

1 reference

31 March 2018

T Dolezal

3

1 reference

31 March 2018

G Kobelt

4

1 reference

31 March 2018

E Havrdova

5

1 reference

31 March 2018

publication date

30 September 2011

1 reference

31 March 2018

Multiple Sclerosis Journal

published in

1 reference

31 March 2018

volume

18

1 reference

31 March 2018

issue

5

1 reference

31 March 2018

page(s)

662-668

1 reference

31 March 2018

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life of patients with multiple sclerosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life in multiple sclerosis in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life of multiple sclerosis in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life of multiple sclerosis in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

The cost of multiple sclerosis in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life of multiple sclerosis in Austria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Costs and quality of life of multiple sclerosis in Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Pharmacoeconomic considerations in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

The epidemiology of multiple sclerosis in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511424422

21 January 2018

Identifiers

DOI

10.1177/1352458511424422

1 reference

31 March 2018

1 reference

31 March 2018